> ## Content Index > Fetch the complete content index at: https://www.intercepta.ai/blog/llms.txt > Use this file to discover other available public pages before exploring further. # Clinically Proven, Except It Was Not - URL: https://www.intercepta.ai/blog/ftc-substantiation-clinically-proven/ - Published: 2026-08-13T09:00:00.000Z - Updated: 2026-08-13T09:00:13.000Z - Description: When an advertiser claims a level of proof it cannot support, the claim itself is the violation, whatever the disclosures say. What the FTC substantiation standard requires before you publish, and why pointing to a study is not the same as holding the evidence. - Author: Edward Sweigart - Tags: Healthcare, Marketing Compliance, advertising compliance, Regulatory A company sold dietary supplements that it advertised as clinically proven to help children grow taller. In July 2026, the United States Federal Trade Commission finalised a settlement order against it. The regulator alleged that the height claim was unsubstantiated. Under the substantiation standard, asserting proof the business could not support is, on its own, a violation. In this case, the standard the Federal Trade Commission (FTC) applied is long established. It requires an advertiser to hold a reasonable basis for a claim before making it, a requirement in place since 1972\. For a health-related claim, that basis must be competent and reliable scientific evidence. The requirement turns on evidence rather than presentation. A claim can be accurate, clearly labelled and fully disclosed, and still violate the rules, because a claim that asserts a level of proof the business does not hold is deceptive on that ground alone. The case involved two grounds, the deceptive reviews and the height claim the business could not support. This piece examines the substantiation failure. ## The claim was a violation on its own According to the FTC, the company had sold supplements marketed to increase height in children and teenagers since at least 2020\. It reached parents and young people through social media, search advertising, email and its own website, with claims that included “The Only Supplement Clinically Proven to Help Height Growth”. Alongside findings about deceptive reviews, the regulator alleged that the claims were unsubstantiated because the business did not hold the competent and reliable scientific evidence needed to support them. The failure was the claim itself, an assertion of a proven effect that the evidence did not support. When the order was finalised, it imposed a judgment of $4 million, partially suspended after payment of $750,000 based on an inability to pay the full amount. It also barred the business from making health claims of that kind unless it holds competent and reliable scientific evidence to support them. It does not require the business to add a label, a disclosure or a disclaimer. It requires the business to hold the evidence, or to stop making the claim. ## The evidence the standard requires The standard the regulator applied is not new, and it is not unique to this case. For claims about the health benefits or safety of foods, dietary supplements and other health-related products, the required support is competent and reliable scientific evidence. For a claim that a product produces a specific health benefit, the FTC standard generally requires randomised, controlled human clinical testing. The more serious the claim, the higher the bar. A claim that a product treats, cures, mitigates or prevents a disease calls for the kind of rigorous clinical evidence that a regulator would expect to see for a therapeutic effect. ![Ladder showing one constant standard, competent and reliable scientific evidence, with the required rigour rising from clinical testing for a specific health or condition claim to the most rigorous clinical evidence for a disease claim; establishment phrases apply across every rung.](https://www.intercepta.ai/blog/content/images/2026/08/Clinically-Proven---Fig-1-One-Standard-Rising-Rigour.png) The standard is the same for every claim. Only the required rigour rises, from clinical testing to the most rigorous for a disease claim. The business has to hold the evidence before the claim is published. Publishing first and substantiating later does not satisfy the standard, whatever the later evidence shows. The duty binds more than the brand. Under the guidance, “all parties who participate directly in marketing and promotion, or who have authority to control those practices, have an obligation to make sure that claims are presented truthfully and to check the adequacy of the support for those claims”. The regulator has, in appropriate circumstances, taken action against advertising agencies, distributors, retailers and expert endorsers engaged in deceptive marketing, as well as against product marketers. ## Pointing to a study is not the same as having the required scientific evidence The company that sold height supplements did have a study to point to. Its support, according to the regulator, was a single company-sponsored study that was too small, ran for too short a period, lacked proper randomisation and did not control for factors such as the participants’ sleep and nutrition. A harder version of the same failure is a study built so that no result could support the claim. The FTC brought an action in June 2026, in a matter that remains before the court, against a company marketing supplements for children with claims that the products could treat or improve serious mental health conditions, including depression, anxiety and attention disorders. These were specific assertions about clinical outcomes in children, promoted as “science backed” and, in places, as “clinically proven”. The company did point to studies. The regulator’s position is that they are “deeply flawed”. The one offered for one of the children’s products used no placebo control group and included only ten participants. A study of that design provides no way to separate the effect of the product from chance, from expectation, or from the ordinary variation that appears in any small group over time. A single small trial with no control, a testimonial, or a theory about how an ingredient works that no human study has confirmed, will generally not meet the standard on its own, however sincerely it is offered. In this matter, the FTC also alleged that the conduct breached an order made in a separate matter years earlier, which already required competent and reliable scientific evidence for health claims, and whose terms extended not only to the party that entered into it but to anyone acting in concert with them. ![Two anonymised enforcement matters shown in parallel, each with the alleged claim and the alleged flaws in the study it relied on, over a banner noting neither held the required scientific evidence.](https://www.intercepta.ai/blog/content/images/2026/08/Clinically-Proven---Fig-2-Study-Not-Evidence.png) Two matters, one failure. Each pointed to a study the regulator alleged fell short of the required scientific evidence. ## The design decides what a study can show The guidance sets out several principles that the scientific community treats as basic to the validity of test results, and it expects a marketer to assess research against them whether the marketer commissioned it or a third party produced it. A study should compare a treatment group against a control, because improvement in the treatment group alone can come from the placebo effect, from ordinary change over time, or from practice at the test itself. The two groups should be randomised or carefully matched so that they are alike, and both the participants and the researchers should be blind to who is in which. Results must be statistically significant, and they must also be large enough to mean something to the person taking the product, since an effect can be real and still be too small to matter. The study offered in support of the children’s supplement used no placebo control group, the ideal form of the first of these principles. Research that falls short of them is more prone to bias and to confounding factors, and the guidance says such studies generally will not meet the standard, which is a presumption rather than an automatic disqualification. The principles give a marketing team a set of questions to put to a study it has been handed, rather than a document to accept on trust. ![Five questions to put to a study: was there a control group, were the groups randomised, were both sides blind, was it statistically significant, and was the effect large enough to matter.](https://www.intercepta.ai/blog/content/images/2026/08/Clinically-Proven---Fig-3-Five-Questions.png) Five questions to put to a study before relying on it, from whether it had a control group to whether the effect was large enough to matter. ## The failure is in the claim, not its presentation It is worth being precise about what this failure is, and what it is not, because the distinction changes how a business should review its content. A different failure, content that does not make clear that it is marketing at all, turns on the concealed origin of the message rather than the accuracy of any claim within it. The enforcement here involved that failure as well, and a published companion piece, [Hidden Advertisements in Health Marketing](https://www.intercepta.ai/blog/hidden-ads-disclosure-rules-ftc-asa-cma/), examines it as a pattern. This piece isolates the other axis. Suppose a business remedies every disclosure problem in health marketing copy, so that the labels are present, the commercial intent is clear, and every material connection is declared. Even then, the content can be non-compliant, because a review for disclosure does not ask whether the firm holds the evidence for what it claims. Accuracy of presentation and adequacy of evidence are two separate tests. Content has to pass both. ## The copy shows which claims need evidence The claims which trigger the substantiation standard do not depend on a business’s internal operations. They are usually apparent from the content itself. A phrase such as “clinically proven” is a claim about what evidence exists and how strong it is. The same is true of copy that states studies show an effect, that calls a product scientifically backed, or that claims a product reduces, improves or treats a named condition. A claim to treat, cure, mitigate or prevent a disease demands the most rigorous evidence. A reader can see the claim in the copy itself, along with the level of proof it asserts and whether that proof would need clinical evidence to support it. This can happen before the content reaches an audience, at the point the copy is being finalised anyway. This holds equally for content that is already live. A claim the business could not substantiate does not become compliant by having been published some time ago. The question a business needs to ask of every health claim is not only whether it reads well, but whether the firm holds what the copy asserts. ## Validating the claim before it is published In both cases the substantiation allegation was the same, that the business advertised a level of proof it did not hold, and in each the study it pointed to did not answer the claim. Preventing that means settling the evidence before the claim is published, and confirming that it answers the claim actually made. Validating a piece of marketing against the substantiation standard identifies the claims that carry an evidence obligation on every asset a business publishes. Validation does not confirm whether the underlying studies exist or whether the evidence is adequate. It identifies the claim that requires evidence, so that the compliance team can assess what the firm actually holds against what the content asserts, before publication rather than after a regulator asks. The advertiser that treats the accuracy of a claim as the only question, or that treats the existence of a study as the end of the matter, will keep publishing content that asserts proof it does not hold. The claim reads as confident. It may even be made in good faith. Neither of those is the same as being substantiated, and in the end it is the claim, not its presentation, that the standard measures. ![Two paths: holding the evidence then publishing meets the substantiation standard, while publishing first and seeking evidence after a regulator asks is unsubstantiated.](https://www.intercepta.ai/blog/content/images/2026/08/Clinically-Proven---Fig-4-Hold-Evidence-Before-Publish.png) Substantiation is a matter of timing. Evidence held before publication meets the standard; evidence sought after a regulator asks does not. ## Before you publish Intercepta AI validates marketing content against more than 1,100 regulatory rules across the United States, United Kingdom, European Union, Canada, Australia and New Zealand, surfacing the claims that carry a compliance obligation and mapping each to the rule that governs it, for the compliance team to review. The decision on every finding stays with them. [Try Intercepta AI](https://intercepta.ai/?ref=intercepta.ai) Your first three scans are free. No payment method required. ## Sources - [Federal Trade Commission, Health Products Compliance Guidance, December 2022](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance?ref=intercepta.ai) (the competent-and-reliable-scientific-evidence standard for claims about health-related products, and the obligation on parties who participate directly in marketing and promotion, or who have authority to control those practices). - [Federal Trade Commission Act, Sections 5, 12 and 15 (15 U.S.C. 45, 52 and 55)](https://www.ftc.gov/legal-library/browse/statutes/federal-trade-commission-act?ref=intercepta.ai) (Section 5 prohibits unfair or deceptive acts or practices and is the basis for the requirement to hold substantiation before a claim is made; Section 12 prohibits the dissemination of false advertisements for foods, drugs, devices, services and cosmetics; Section 15 defines a false advertisement as one that is misleading in a material respect). - [Federal Trade Commission, Policy Statement Regarding Advertising Substantiation (1984)](https://www.ftc.gov/legal-library/browse/ftc-policy-statement-regarding-advertising-substantiation?ref=intercepta.ai), appended to Thompson Medical Co., 104 F.T.C. 648, 839 (1984), setting out the requirement that advertisers hold a reasonable basis for objective claims before dissemination; the doctrine was first announced in Pfizer, Inc., 81 F.T.C. 23 (1972). - Federal Trade Commission enforcement action, final order 15 July 2026, matter File No. 242-3093, following the administrative complaint and proposed consent order of 13 April 2026 (dietary supplements advertised as clinically proven to increase height in children and teenagers; claims alleged unsubstantiated for lack of competent and reliable scientific evidence; judgment of $4 million partially suspended after payment of $750,000 on inability to pay, with a prospective bar on unsubstantiated health claims). - Federal Trade Commission enforcement action, complaint of 2 June 2026 and contempt motion of 12 June 2026, matter File No. 252-3140, Case No. 2:26-cv-05900 (C.D. Cal.) (dietary supplements marketed for children with claims to treat or improve depression, anxiety and attention disorders; alleged unsubstantiated; study cited in support described as using no placebo control group and including only ten participants; alleged breach of an order made in a separate matter years earlier; matter unresolved).